According to GuruFocus Insider Data, the recent CFO sales were: Acadia Healthcare Co. Inc. (ACHC, Financial), Facebook Inc. (FB, Financial) and Regeneron Pharmaceuticals Inc. (REGN, Financial).
Acadia Healthcare: CFO David M. Duckworth sold 31,129 shares
On Aug. 14, CFO David M. Duckworth sold 31,129 shares at an average price of $80.47. The price of the stock has decreased by 8.43%. Acadia Healthcare Co Inc. has a market cap of $5.28 billion and its shares were traded at around $73.69. The company has a P/E ratio of 48.36 and P/S ratio of 3.28.
Acadia Healthcare Co. Inc. announced its 2015 second-quarter results with revenues of $453.66 million and gross profit of $433.12 million; the net income was $33.84 million. The 2014 total revenue was $1.00 billion, a 41% increase from the 2013 total revenue. The 2014 gross profit was $956.18 million, a 41% increase from the 2013 gross profit. The 2014 net income was $83.04 million.
On Aug. 14, CEO, 10% owner Joey A. Jacobs sold 92,066 shares at an average price of $80.47. The price of the stock has decreased by 8.43%. On 08/14/2015, COO, 10% owner Ronald Morgan Fincher sold 37,294 shares at an average price of $80.47. The price of the stock has decreased by 8.43%. On Aug. 14, 10% owner Jack E. Polson sold 20,230 shares at an average price of $80.47. The price of the stock has decreased by 8.43%.
Facebook: CFO David M. Wehner sold 8,072 shares
On Aug. 20, CFO David M. Wehner sold 8,072 shares at an average price of $93.56. The price of the stock has decreased by 8.02%. Facebook has a market cap of $242.48 billion and its shares were traded at around $86.06. The company has a P/E ratio of 87.96 and P/S ratio of 16.35.
Facebook announced its 2015 second-quarter results with revenues of $4.04 billion and gross profit of $3.37 billion; the net income was $715 million. The 2014 total revenue was $12.47 billion, a 58% increase from the 2013 total revenue. The 2014 gross profit was $10.31 billion, a 72% increase from the 2013 gross profit. The 2014 net income was $2.93 billion.
On Aug. 20, Director Susan Desmond-Hellmann sold 625 shares at an average price of $93.56. The price of the stock has decreased by 8.02%. On 08/19/2015, VP Marketing and Bus. Part. David B. Fischer sold 25,000 shares at an average price of $94.65. The price of the stock has decreased by 9.08%. On Aug. 18, VP, Gen. Counsel and Secretary Colin Stretch sold 12,555 shares at an average price of $93.77. The price of the stock has decreased by 8.22%.
Regeneron Pharmaceuticals: SVP Finance and CFO Robert E Landry sold 4,000 shares
On Aug. 5, SVP Finance and CFO Robert E Landry sold 4,000 shares at an average price of $592.84. The price of the stock has decreased by 11.08%. Regeneron Pharmaceuticals Inc. has a market cap of $54.66 billion and its shares were traded at around $527.18. The company has a P/E ratio of 131.28 and P/S ratio of 17.75.
Regeneron Pharmaceuticals Inc. announced its 2015 second-quarter results with revenues of $998.62 million and gross profit of $869.61 million; the net income was $194.64 million. The 2014 total revenue was $2.82 billion, a 34% increase from the 2013 total revenue. The 2014 gross profit was $2.61 billion, a 34% increase from the 2013 gross profit. The 2014 net income was $348.07 million.
On July 27, 10% owner Sanofi bought 10,639 shares at an average price of $537.48. The price of the stock has decreased by 1.92%. On Aug. 14, SVP Clinical Development and Reg Peter Powchik sold 23,485 shares at an average price of $573.38. The price of the stock has decreased by 8.06%. On 08/12/2015, Director Christine A Poon sold 112 shares at an average price of $564.16. The price of the stock has decreased by 6.55%.
